Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $11.80.

A number of analysts have issued reports on the company. D. Boral Capital began coverage on Compass Therapeutics in a research report on Monday. They issued a "buy" rating and a $32.00 target price for the company. Leerink Partners lowered Compass Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Monday, November 11th. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Finally, Leerink Partnrs lowered shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Ground Swell Capital LLC bought a new position in shares of Compass Therapeutics in the second quarter valued at approximately $124,000. Barclays PLC boosted its holdings in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company's stock valued at $314,000 after purchasing an additional 112,614 shares during the period. Renaissance Technologies LLC boosted its holdings in Compass Therapeutics by 99.7% in the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock valued at $141,000 after purchasing an additional 70,200 shares during the period. Panagora Asset Management Inc. purchased a new position in shares of Compass Therapeutics during the 2nd quarter valued at $68,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Compass Therapeutics in the third quarter worth $79,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

Compass Therapeutics Price Performance

Shares of Compass Therapeutics stock traded up $0.13 during trading hours on Monday, hitting $1.51. 361,647 shares of the company's stock traded hands, compared to its average volume of 438,909. Compass Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.34. The company has a fifty day simple moving average of $1.65 and a 200-day simple moving average of $1.41. The stock has a market capitalization of $207.76 million, a price-to-earnings ratio of -4.08 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. On average, analysts forecast that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.